Third Security

Fitnet Corporation develops a mobile fitness application that enhances personal workout experiences by integrating biometric sensors and fitness coaching. The application offers a variety of video workouts, including yoga, strength training, and cardio, while utilizing the device's camera to analyze user performance in real-time. This technology provides users with a performance score based on their synchronicity with trainers, offering immediate feedback during exercise sessions. Since its launch, the Fitnet application has been adopted in over 190 countries, with users collectively burning more than 10 million calories. The company, originally known as KinectHealth Corporation, was founded in 2013 and is headquartered in Blacksburg, Virginia.

Heyo, Inc. is a company that specializes in social media marketing services, offering tools and solutions for businesses to enhance their online presence. Founded in 2010 and based in Blacksburg, Virginia, Heyo provides products such as customizable templates, promotions, and drag-and-drop builders that enable users to create Facebook contests, sweepstakes, and mobile-optimized landing pages. The company's software allows businesses to effectively engage with customers on Facebook, a key platform for both small and large enterprises. Additionally, Heyo is recognized for its capabilities in mobile app development, facilitating the creation of mobile-friendly content that can reach customers directly. Formerly known as Lujure Media, Inc., Heyo operates as a subsidiary of Votigo, Inc., focusing on helping organizations drive traffic, generate leads, and increase sales through innovative digital campaigns.

Transgenomic, Inc. is a biotechnology company that specializes in the purification and analysis of nucleic acids for the life sciences sector, focusing on molecular genetics and diagnostics. It offers genetic variation analytical services to various markets, including medical research, clinical, and pharmaceutical sectors. The company operates three key divisions: Transgenomic Clinical Laboratories, which provides molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory supporting pre-clinical and clinical trials for oncology drugs; and Transgenomic Diagnostic Tools, which manufactures equipment and reagents for molecular testing and cytogenetics. Transgenomic is recognized as a leader in cardiac genetic testing, with innovative products like the C-GAAP test designed to identify gene mutations associated with cardiac disorders. With a customer base that spans over 50 countries, including academic institutions and commercial entities, the company is committed to advancing personalized medicine and recognizes substantial growth opportunities by leveraging its technologies and expertise.

AmpliPhi Biosciences is a biopharmaceutical company that specializes in developing bacteriophage-based therapies for bacterial infections. By utilizing naturally occurring viruses known as bacteriophages, the company aims to address various bacterial infections, particularly those caused by drug-resistant strains prevalent in hospital environments. AmpliPhi has established a drug development and manufacturing platform that enables the rapid creation and production of multiple phage-based therapies. The company’s initial focus is on treating acute and chronic infections affecting the lungs, sinuses, and gastrointestinal tract. With operations in Richmond, Virginia, Colworth Science Park near London, and outside Sydney, Australia, AmpliPhi is committed to advancing its pipeline of phage therapies to effectively combat targeted bacterial diseases.

Soligenix, Inc., a late-stage biopharmaceutical company based in Princeton, New Jersey, focuses on developing and commercializing treatments for rare diseases and serious side effects of cancer therapies, where there is an unmet medical need. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops therapies such as SGX301 for cutaneous T-cell lymphoma, SGX942 for oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone for gastrointestinal disorders. The Public Health Solutions segment works on biodefense vaccines and therapeutics, including RiVax, a ricin toxin vaccine, and SGX943, a therapeutic candidate for antibiotic-resistant and emerging infectious diseases.

Precigen is a biotechnology company focused on developing synthetic biology solutions. It specializes in designing, building, and regulating gene programs, with its technologies applicable across various end markets. The company's approach involves forming exclusive collaborations with partners who possess specific industry expertise and resources in development, sales, and marketing. This model allows Precigen to commercialize its innovations effectively, bringing new and improved products and processes to market. Its operations are divided into segments, including biopharmaceuticals and Exemplar, and the company generates revenue through technology access fees, royalties, and milestone payments from these collaborations.

Precigen is a biotechnology company focused on developing synthetic biology solutions. It specializes in designing, building, and regulating gene programs, with its technologies applicable across various end markets. The company's approach involves forming exclusive collaborations with partners who possess specific industry expertise and resources in development, sales, and marketing. This model allows Precigen to commercialize its innovations effectively, bringing new and improved products and processes to market. Its operations are divided into segments, including biopharmaceuticals and Exemplar, and the company generates revenue through technology access fees, royalties, and milestone payments from these collaborations.

Synchrony Ventures, established in 2016, is the early-stage venture capital arm of Synchrony Financial, a leading U.S. consumer financial services company. Based in San Francisco, the firm invests in innovative, early-stage companies within the financial services, healthcare, and commerce sectors, aligning with Synchrony's core business areas. Synchrony Ventures provides not only capital but also expertise, partnership, and access to Synchrony's extensive network, helping portfolio companies achieve their unique ambitions.

Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.

Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.

Precigen is a biotechnology company focused on developing synthetic biology solutions. It specializes in designing, building, and regulating gene programs, with its technologies applicable across various end markets. The company's approach involves forming exclusive collaborations with partners who possess specific industry expertise and resources in development, sales, and marketing. This model allows Precigen to commercialize its innovations effectively, bringing new and improved products and processes to market. Its operations are divided into segments, including biopharmaceuticals and Exemplar, and the company generates revenue through technology access fees, royalties, and milestone payments from these collaborations.

LevelVision designs and deploys video display technologies, and provides marketing solutions to the place-based, ambient, and out-of-home marketing industries.

Synchrony Ventures, established in 2016, is the early-stage venture capital arm of Synchrony Financial, a leading U.S. consumer financial services company. Based in San Francisco, the firm invests in innovative, early-stage companies within the financial services, healthcare, and commerce sectors, aligning with Synchrony's core business areas. Synchrony Ventures provides not only capital but also expertise, partnership, and access to Synchrony's extensive network, helping portfolio companies achieve their unique ambitions.

Precigen is a biotechnology company focused on developing synthetic biology solutions. It specializes in designing, building, and regulating gene programs, with its technologies applicable across various end markets. The company's approach involves forming exclusive collaborations with partners who possess specific industry expertise and resources in development, sales, and marketing. This model allows Precigen to commercialize its innovations effectively, bringing new and improved products and processes to market. Its operations are divided into segments, including biopharmaceuticals and Exemplar, and the company generates revenue through technology access fees, royalties, and milestone payments from these collaborations.

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Charlottesville, Virginia, focused on developing innovative therapies for life-threatening medical conditions. The company's lead product candidate, transcrocetinate sodium (TSC), aims to enhance oxygen delivery to hypoxic tissues, addressing complications associated with various severe health issues. TSC is currently in Phase III clinical trials for glioblastoma multiforme and Phase II trials for metastatic brain cancer and acute stroke. Additionally, Diffusion is working on RES-529, a PI3K/Akt/mTOR pathway inhibitor that has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development for oncology applications, primarily targeting glioblastoma. The company also has a research collaboration with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to explore TSC's efficacy in patients suffering from acute respiratory distress syndrome related to COVID-19. Founded in 2001, Diffusion Pharmaceuticals is dedicated to addressing critical health challenges through its advanced therapeutic candidates.